June 08, 2022
Men's Health Fair Friday, June 10, 2022 9am - 2pm MLK Jr. Outpatient Center 1670 E. 120th St. Los Angeles, CA 90059 Free Activities Will Include: Health screenings Live DJ! Information from licensed healthcare providers Community resources In-N-Out Burger* Free haircuts* Free swag bags Fun raffles! Ask about recruiter enrollment!!! *First come, first serve for tested individu
Four UCLA Health physicians elected to Association of American Physicians
April 11, 2022
Four UCLA physicians have been elected to the Association of American Physicians, an honor given to no more than 70 physicians per year. UCLA’s 2022 honorees are neurologist Timothy Cloughesy, infectious disease specialist Judith Currier, primary care physician Carol Mangione and cardiologist Kalyanam Shivkumar. Their election brings to 38 the number of AAP members from UCLA and the David Schoo
Injected PrEP: cabotegravir maintains its advantage over four years
February 18, 2022
An update on HPTN 083, the study that established that PrEP given as an injection every two months had superior efficacy to a daily pill in gay and bisexual men and transgender women, was presented this week at the Conference on Retroviruses and Opportunistic Infections (CROI 2022). Four and a half years of data are now available. The efficacy of cabotegravir injections relative to oral PrEP us
PROGRAM
Click on the presentation title or presenter below to watch that specific presentation.
Opening Remarks
Dr. Judith Currier
An Update on COVID-19 Research
Dr. Eric Daar
New Approaches in HIV Prevention
Dr. Raphael Landovitz
An Update on COVID-19 Research
Dr. David Goodman-Meza
An Update on HIV Cure Research
Dr. Kara Chew
New study for the treatment of latent CMV infection in HIV positive adults.
This is an open-label, controlled study, conducted at US sites to evaluate the anti-inflammatory effectiveness of the study drug letermovir in adults with HIV and asymptomatic cytomegalovirus (CMV) who are on antiretroviral therapy (ART)-mediated suppression. Participants will be randomly assigned to receive either letermovir once daily or no anti-CMV treatment, for 48 weeks. Interested in Volunteering? Do you want to participate in a study related to HIV & Aging? Explore a treatment that looks at whether an oral drug decreases inflammation. Eligibility Criteria: Age 40 or older HIV with undetectable viral load on HIV treatment for at least 48 weeks Positive for CMV (the study will perform the test) Principal Investigator: Kara Chew, MD, MS For more information, please contact the UCLA CARE Center: [email protected] 310-843-2015 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
CMV Vaccine Study in Adults with Both HIV and CMV Who Are on ART
A5355 is a phase II, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of two injections of MVA Vaccine Encoding CMV antigens (Triplex®) in adults with both HIV and CMV. Participants will be randomized in a 2:1 ratio to receive either two injections of CMV-MVA Triplex® or placebo administered at study Entry/Day 0 and week 4. Participants will have follow-up visits in person or by phone for 92 weeks after the second injection, for a total of 96 weeks of follow-up. During the study, participants will have blood, urine, genital secretions, and oral secretions collected. Interested in Volunteering? CMV infection is common in people living with HIV and often silent, but causes chronic inflammation. This study is testing an investigational vaccine that targets CMV called Triplex®. Basic Eligibility Criteria: Age: 18-65 years old Living with HIV and positive for CMV (study will do the test for CMV) On continuous HIV treatment for at least 48 weeks CD4 count > 250 Principal Investigator: Kara Chew, MD, MS For more information, please contact the UCLA CARE Center: [email protected] 310-843-2015 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
A5386: Phase I clinical trial for HIV+ individuals who are undetectable
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI). Interested in Volunteering? This study is looking for people with HIV who are taking HIV treatment and whose viral load is undetectable. The study will see if an experimental product called IL-15 given alone or in combination with two antibodies directed against HIV, called broadly neutralizing antibodies (bNAbs), is safe and leads to control of HIV. Half of the participants will receive 8 doses of IL-15 given every 3 weeks and half will receive 8 doses of IL-15 given every 3 weeks plus the bNAbs. After receiving these products, participants will temporarily stop taking their HIV treatment and will be monitored closely to see if their HIV is controlled without HIV treatment. Basic Eligibility Criteria: Age: 18-65 years old Status: HIV Positive Continuous HIV treatment: at least 96 weeks Viral load: Undetectable at least 96 weeks Coinfection: No active hepatitis B or C infection CD4 count: More than 500 Principal Investigator: Kara Chew, MD, MS For more information, please contact the UCLA CARE Center: [email protected] 310-843-2015 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
